
|Videos|December 4, 2021
Lutetium 177 PSMA enhances QOL in patients with mCRPC
Author(s)Urology Times staff
"The results of this trial impacted practice globally,” says Michael J. Morris, MD.
Advertisement
In this video, Michael J. Morris, MD, discusses the background, findings, and takeaways of the VISION trial, which was presented recently at the 2021 Society of Urologic Oncology Annual Meeting. Morris is the section head of prostate cancer in the GU oncology service at the Memorial Sloan Kettering Cancer Center in New York, New York.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: AUA 2026 Update on Prostate Cancer Early Detection, With Badrinath R. Konety, MBBS
2
FDA approves enfortumab vedotin plus pembrolizumab for MIBC
3
Daniel George, MD, on the significance of the capivasertib approval for PTEN-deficient prostate cancer
4
EV plus pembro approval reframes first conversation in MIBC diagnosis
5













